Resveratrol Bioavailability After Oral Administration: A Meta-Analysis of Clinical Trial Data

source extracted confidence: high 2026-04-09
#resveratrol #biological-availability #humans #administration-oral #clinical-trials-as-topic

Resveratrol Bioavailability After Oral Administration: A Meta-Analysis of Clinical Trial Data

Szymkowiak et al., 2025 | Phytother Res | Meta Analysis

Citation

Szymkowiak Izabela, Marcinkowska Justyna, ... Murias Marek. Resveratrol Bioavailability After Oral Administration: A Meta-Analysis of Clinical Trial Data. Phytother Res. 2025-Jan;39(1):453-464. doi:10.1002/ptr.8379

Abstract

Annually, a growing body of studies substantiates the health advantages of polyphenolic compounds, yet their practical application is constrained by swift metabolism and low bioavailability. Resveratrol, a stilbene derivative showcasing typical polyphenolic traits, is particularly noteworthy. Despite abundant bioavailability data from in vitro and animal studies, applying these findings to humans demands nuanced consideration. The objective of this article is to conduct a meta-analysis on clinical trial data, systematically assessing the oral bioavailability of resveratrol and deriving meaningful insights into its efficacy in humans. To achieve this goal, we thoroughly examined publications across five major global databases: PubMed, Cochrane Library, Scopus, Embase, and Science Direct. The study exclusively included clinical trials involving healthy adults, where pharmacokinetic parameters were measured following the oral administration of at least one dose of resveratrol as a single preparation. For the meta-analysis data extraction, the mean score and standard deviation (SD) were included. Heterogeneity, degree of inconsistency between studies, and meta-regression were assessed. From these searches, we scrutinized data from 84 oral administrations encompassing nine resveratrol doses ranging from 25 to 5000 mg. Our findings indicate a linear increase in the amount of free resveratrol entering the bloodstream with the administered dose, while T max values remain unaffected. The mean maximum plasma concentration of resveratrol (31.07 ng/mL) closely mirrors the mean C max observed in the group administered a medium resveratrol dose ranging from 100 to 500 mg (33.59 ng/mL). This similarity implies the appropriateness of employing these specific doses of resveratrol, taking into consideration both its bioavailability and very low risk of potential side effects. However, the analysis of available human oral bioavailability data is constrained by methodological inconsistencies prevalent in existing studies. The meta-analysis underscores substantial heterogeneity, underscoring the imperative for multiple studies to rectify this prevailing trend.

Key Findings

The meta-analysis underscores substantial heterogeneity, underscoring the imperative for multiple studies to rectify this prevailing trend.

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population See abstract
Sample Size See abstract
Age Range See abstract
Condition See abstract

MeSH Terms

  • Resveratrol
  • Biological Availability
  • Humans
  • Administration, Oral
  • Clinical Trials as Topic
  • Stilbenes
  • Adult

Evidence Classification

  • Level: Meta Analysis
  • Publication Types: Journal Article, Meta-Analysis, Review
  • Vertical: resveratrol

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09